Astellas Pharma Stock Debt To Equity
| ALPMF Stock | USD 10.37 0.12 1.17% |
Astellas Pharma fundamentals help investors to digest information that contributes to Astellas Pharma's financial success or failures. It also enables traders to predict the movement of Astellas Pink Sheet. The fundamental analysis module provides a way to measure Astellas Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Astellas Pharma pink sheet.
Astellas |
Astellas Pharma Company Debt To Equity Analysis
Astellas Pharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Astellas Pharma Debt To Equity | 0 % |
Most of Astellas Pharma's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Astellas Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Astellas Pharma has a Debt To Equity of 0.003%. This is 99.99% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The debt to equity for all United States stocks is 99.99% higher than that of the company.
Astellas Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Astellas Pharma's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Astellas Pharma could also be used in its relative valuation, which is a method of valuing Astellas Pharma by comparing valuation metrics of similar companies.Astellas Pharma is currently under evaluation in debt to equity category among its peers.
Astellas Fundamentals
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 26.19 B | |||
| Shares Outstanding | 1.83 B | |||
| Shares Owned By Insiders | 0.37 % | |||
| Shares Owned By Institutions | 50.43 % | |||
| Price To Earning | 25.09 X | |||
| Price To Book | 2.38 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 1.3 T | |||
| Gross Profit | 1.04 T | |||
| EBITDA | 241.52 B | |||
| Net Income | 124.09 B | |||
| Cash And Equivalents | 336.76 B | |||
| Cash Per Share | 184.77 X | |||
| Total Debt | 4.87 B | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 1.34 X | |||
| Book Value Per Share | 861.58 X | |||
| Cash Flow From Operations | 257.44 B | |||
| Earnings Per Share | 0.57 X | |||
| Target Price | 50.0 | |||
| Number Of Employees | 14.52 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 26.66 B | |||
| Total Asset | 2.33 T | |||
| Retained Earnings | 941.23 B | |||
| Working Capital | 491.17 B | |||
| Current Asset | 874.69 B | |||
| Current Liabilities | 383.53 B | |||
| Z Score | 3.0 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 2.25 % | |||
| Net Asset | 2.33 T | |||
| Last Dividend Paid | 25.0 |
About Astellas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Astellas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astellas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astellas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Astellas Pink Sheet
Astellas Pharma financial ratios help investors to determine whether Astellas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.